Welcome to LookChem.com Sign In|Join Free

CAS

  • or

749269-74-7

Post Buying Request

749269-74-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

749269-74-7 Usage

Description

1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is a chemical compound characterized by a cyclopropane ring fused to a carboxylic acid group and a phenyl ring substituted with bromine and fluorine atoms. This unique structure positions it for various applications in organic chemistry, particularly in research and experimental settings.

Uses

Used in Organic Chemistry Research:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid serves as a valuable compound in organic chemistry research, where it is utilized for the study of cyclopropane-containing compounds and their reactions. Its distinct structural features make it a candidate for exploring novel chemical pathways and mechanisms.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is used as a building block or intermediate in the synthesis of new drugs. Its bromine and fluorine substituents can be leveraged to modulate the compound's properties, potentially enhancing its pharmacological activity and selectivity.
Used in Drug Synthesis:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is employed as a key intermediate in the synthesis of complex organic molecules, including pharmaceutical agents. Its reactivity and functional groups can be exploited in various synthetic routes to construct diverse drug candidates with potential therapeutic applications.
Used in the Study of Cyclopropane-Containing Compounds:
1-(4-Bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid is utilized in the investigation of cyclopropane-containing compounds, which are known for their unique properties and applications in various fields. Research on this compound can provide insights into the behavior and potential uses of cyclopropane derivatives in chemistry and medicine.

Check Digit Verification of cas no

The CAS Registry Mumber 749269-74-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,4,9,2,6 and 9 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 749269-74:
(8*7)+(7*4)+(6*9)+(5*2)+(4*6)+(3*9)+(2*7)+(1*4)=217
217 % 10 = 7
So 749269-74-7 is a valid CAS Registry Number.

749269-74-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 16, 2017

Revision Date: Aug 16, 2017

1.Identification

1.1 GHS Product identifier

Product name 1-(4-bromo-3-fluorophenyl)cyclopropane-1-carboxylic acid

1.2 Other means of identification

Product number -
Other names 4-bromo-3-fluorophenylcyclopropanecarboxylic acid

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:749269-74-7 SDS

749269-74-7Relevant articles and documents

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

Shi, Yongjia,Gao, Qian,Xu, Senmiao

, p. 10599 - 10604 (2019/08/28)

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

TETRAHYDROTHIAZEPINE DERIVATIVE

-

, (2014/03/24)

The present invention relates to a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof having an excellent effect of inhibiting 11β-hydroxysteroid dehydrogenase type 1: General formula (I) wherein R1 represents a phenyl group that may be substituted with 1 to 5 group(s) independently selected from substituent group A or a heterocyclic group that may be substituted with 1 to 4 group(s) independently selected from substituent group A; R2 independently represents a halogen atom or a C1-C6 alkyl group; n represents an integer of 0 to 2; and substituent group A represents the group consisting of halogen atoms, C1-C6 alkyl groups, and so forth.

Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates

Schiefer, Isaac T.,Abdul-Hay, Samer,Wang, Huali,Vanni, Michael,Qin, Zhihui,Thatcher, Gregory R. J.

, p. 2293 - 2306 (2011/06/20)

Poor blood-brain barrier penetration of nonsteroidal anti-inflammatory drugs (NSAIDs) has been blamed for the failure of the selective amyloid lowering agent (SALA) R-flurbiprofen in phase 3 clinical trials for Alzheimer's disease (AD). NO-donor NSAIDs (NO-NSAIDs) provide an alternative, gastric-sparing approach to NSAID SALAs, which may improve bioavailability. NSAID analogues were studied for anti-inflammatory activity and for SALA activity in N2a neuronal cells transfected with human amyloid precursor protein (APP). Flurbiprofen (1) analogues were obtained with enhanced anti-inflammatory and antiamyloidogenic properties compared to 1, however, esterification led to elevated A 1-42 levels. Hybrid nitrate prodrugs possessed superior anti-inflammatory activity and reduced toxicity relative to the parent NSAIDs, including clinical candidate CHF5074. Although hybrid nitrates elevated A 1-42 at higher concentration, SALA activity was observed at low concentrations (1 μM): both A1-42 and the ratio of A 42/A1-40 were lowered. This biphasic SALA activity was attributed to the intact nitrate drug. For several compounds, the selective modulation of amyloidogenesis was tested using an immunoprecipitation MALDI-TOF approach. These data support the development of NO-NSAIDs as an alternative approach toward a clinically useful SALA.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 749269-74-7